We are proud to share that Axtria has made NJBIZ’s Fast 50 list of the fastest growing companies in New Jersey. It is our fourth year on the list, and we are ranked 11th for 2017.
Axtria is extremely proud to rank in Crain’s New York Business Fast 50 List for 2017. The ranking highlights the city's 50 fastest-growing companies with its annual Fast 50 feature. It celebrates the success of innovative companies and recognizes their business strategies and accelerated revenue growth.
Some of the most rewarding work we are involved in at Axtria right now is in the Health Economics and Outcomes Research (HEOR) space, where we are partnering with our clients to help demonstrate the value of their medications and get them to the patients who need them. Challenges in the healthcare space—including rising costs, an aging population, advanced technology, and increased patient awareness of medical options—have resulted in an increase in evaluating medications from an HEOR perspective. Through our modelling and analytical work, we work with clients and key opinion leaders (KOLs) to identify which patients would benefit from various treatment options and the impact those treatments could have on patient health.
The final countdown to the Veeva Commercial Summit has begun and we are only a few days away from one of the most exciting events on the pharma calendar. This year, besides our interesting lineup of activities at our booth we have a very compelling Commercial Excellence Survey report to share with you. We recently conducted this survey to understand the current state of commercial excellence across the industry.
Axtria is excited to be back as a gold sponsor at the Veeva Summit 2017. This is always one of our favorite events of the year, with so many industry professionals and Veeva experts together in one place. We hear there will be more than 1,200 of us this year in Philadelphia, which just highlights the significance of this event and the themes covered.
We always save the best until last, and PMSA 2017 is no exception. On Wednesday 26th April, we will conclude the conference with an insightful presentation from Asheesh Sharma and Vineet Rathi on Data Strategy and Governance: A Strategic Enabler of Next Generation Analytics and Insight Driven Commercial Excellence.
As the industry shifts from volume to value based models, it is becoming necessary for Pharmaceutical companies to demonstrate the value their brands deliver through outcomes and evidence based studies. One example of such study is economic burden of inadequate symptom control.
The following blog is an expanded summary of proposed research accepted for delivery at the upcoming 22nd ISPOR Annual International Meeting, Research Poster Presentations - Session I, entitled “Health Care Use & Policy Studies”, to be held in the John B. Hynes Convention Center (Level 2) in Boston on Monday May 22, 2017 from 8:30am-2:30pm. The poster author discussion hour will be from 1:00-2:00pm.
Following on from our first PMSA blog post on the pre-conference tutorial, we would now like to draw your attention to the thought-leading presentations we have planned on April 25th.